CVAC Valuation

CureVac NV

Add to Watchlist

Advanced Chart

5.460

+0.02(0.368%)1D

Overview
Forecast
Valuation
Earnings

CVAC Relative Valuation

CVAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CVAC is overvalued; if below, it's undervalued.

Historical Valuation

CureVac NV (CVAC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 14.21 is considered Overvalued compared with the five-year average of -7.97. The fair price of CureVac NV (CVAC) is between 1.10 to 3.84 according to relative valuation methord. Compared to the current price of 5.46 USD , CureVac NV is Overvalued By 42.18%.

Relative Value

Fair Zone

1.10-3.84

Current Price：5.46

42.18%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.62

P/B

Median3y

2.07

Median5y

5.70

14.16

FCF Yield

Median3y

-31.84

Median5y

-22.26

Competitors Valuation Multiple

The average P/S ratio for CVAC's competitors is 9.24, providing a benchmark for relative valuation. CureVac NV Corp (CVAC) exhibits a P/S ratio of 14.27, which is 54.48% above the industry average. Given its robust revenue growth of -92.78%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap